Literature DB >> 19211725

Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia.

Meijing Wang1, Yue Wang, Brent Weil, Aaron Abarbanell, Jeremy Herrmann, Jiangning Tan, Megan Kelly, Daniel R Meldrum.   

Abstract

Females have a lower incidence of heart failure and improved survival after myocardial ischemia-reperfusion (I/R) compared with males. Although estrogen-suppressed cardiomyocyte apoptosis may be mediated through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, it is unclear whether this action is mediated via estrogen receptor beta (ERbeta). Therefore, we hypothesized that ERbeta mediates estrogen-induced cardioprotection through PI3K/Akt and antiapoptotic signaling in females but not in males. Isolated male and female hearts from ERbeta knockout (ERbetaKO) and wild-type (WT) mice (n = 5 mice/group) were subjected to 20-min ischemia followed by 60-min reperfusion (Langendorff). Ablation of ERbeta significantly decreased postischemic recovery of left ventricular developed pressure in female, but not male, hearts. Reduced activation of PI3K and Akt was noted in female ERbetaKO hearts, which was associated with increased expression of caspase-3 and -8, as well as decreased Bcl-2 levels compared with WT. However, myocardial STAT3, SOCS3 (suppressor of cytokine signaling 3), VEGF, and TNF receptors 1 and 2 levels did not change in ERbetaKO of either sex following I/R. Furthermore, deficiency of ERbeta increased myocardial JNK activation in females but increased ERK1/2 activity in males during acute I/R. We conclude that ERbeta mediates myocardial protection via upregulation of PI3K/Akt activation, decreased caspase-3 and -8, and increased Bcl-2 in female hearts following I/R. These findings provide evidence of ERbeta-mediated PI3K/Akt and antiapoptotic signaling in the myocardium and may lend insight into the mechanistic pathways behind the observed variation in clinical outcomes between males and females after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211725      PMCID: PMC2698598          DOI: 10.1152/ajpregu.00045.2009

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  25 in total

1.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase.

Authors:  T Simoncini; A Hafezi-Moghadam; D P Brazil; K Ley; W W Chin; J K Liao
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

2.  17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling.

Authors:  Richard D Patten; Isaac Pourati; Mark J Aronovitz; Jason Baur; Flore Celestin; Xin Chen; Ashour Michael; Syed Haq; Simone Nuedling; Christian Grohe; Thomas Force; Michael E Mendelsohn; Richard H Karas
Journal:  Circ Res       Date:  2004-09-02       Impact factor: 17.367

3.  Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II).

Authors:  T Simon; M Mary-Krause; C Funck-Brentano; P Jaillon
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

4.  Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo.

Authors:  T Matsui; J Tao; F del Monte; K H Lee; L Li; M Picard; T L Force; T F Franke; R J Hajjar; A Rosenzweig
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

5.  Impact of estrogen replacement on ventricular myocyte contractile function and protein kinase B/Akt activation.

Authors:  Jun Ren; Kadon K Hintz; Z K Fariba Roughead; Jinhong Duan; Peter B Colligan; Bonnie H Ren; Kap J Lee; Huawei Zeng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-01-16       Impact factor: 4.733

6.  Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 to 1991. Presentation, diagnosis, treatment, and 28-day case fatality of 3991 events in men and 1551 events in women.

Authors:  H Tunstall-Pedoe; C Morrison; M Woodward; B Fitzpatrick; G Watt
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

7.  Mechanisms of sex differences in TNFR2-mediated cardioprotection.

Authors:  Meijing Wang; Paul R Crisostomo; Troy A Markel; Yue Wang; Daniel R Meldrum
Journal:  Circulation       Date:  2008-09-30       Impact factor: 29.690

8.  Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy.

Authors:  Yoshihiro Higuchi; Charles F McTiernan; Carole B Frye; Brian S McGowan; Tung O Chan; Arthur M Feldman
Journal:  Circulation       Date:  2004-03-29       Impact factor: 29.690

9.  Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions.

Authors:  Linda Björnström; Maria Sjöberg
Journal:  Mol Endocrinol       Date:  2002-10

10.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

View more
  59 in total

1.  Oestrogen prevents cardiomyocyte apoptosis by suppressing p38α-mediated activation of p53 and by down-regulating p53 inhibition on p38β.

Authors:  Han Liu; Ali Pedram; Jin Kyung Kim
Journal:  Cardiovasc Res       Date:  2010-08-19       Impact factor: 10.787

2.  Estrogenic Impact on Cardiac Ischemic/Reperfusion Injury.

Authors:  Sivaporn Sivasinprasasn; Krekwit Shinlapawittayatorn; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Cardiovasc Transl Res       Date:  2016-01-19       Impact factor: 4.132

3.  Impact of simulated microgravity on microvascular endothelial cell apoptosis.

Authors:  Chun-Yan Kang; Lin Zou; Ming Yuan; Yang Wang; Tian-Zhi Li; Ye Zhang; Jun-Feng Wang; Yan Li; Xiao-Wei Deng; Chang-Ting Liu
Journal:  Eur J Appl Physiol       Date:  2011-02-02       Impact factor: 3.078

Review 4.  The effects of oestrogens and their receptors on cardiometabolic health.

Authors:  Eugenia Morselli; Roberta S Santos; Alfredo Criollo; Michael D Nelson; Biff F Palmer; Deborah J Clegg
Journal:  Nat Rev Endocrinol       Date:  2017-03-17       Impact factor: 43.330

Review 5.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

Review 6.  Age-related differences in cardiac ischemia-reperfusion injury: effects of estrogen deficiency.

Authors:  Donna H Korzick; Timothy S Lancaster
Journal:  Pflugers Arch       Date:  2013-03-23       Impact factor: 3.657

7.  The Negative Chronotropic Effect in Rat Heart Stimulated by Ultrasonic Pulses: Role of Sex and Age.

Authors:  Olivia C Coiado; William D O'Brien
Journal:  J Ultrasound Med       Date:  2017-01-10       Impact factor: 2.153

8.  Estrogen Receptors Are Involved in the Neuroprotective Effect of Silibinin in Aβ1-42-Treated Rats.

Authors:  Xiaoyu Song; Bo Liu; Lingyu Cui; Biao Zhou; Lu Liu; Weiwei Liu; Guodong Yao; Mingyu Xia; Toshihiko Hayashi; Shunji Hattori; Yuko Ushiki-Kaku; Shin-Ichi Tashiro; Takashi Ikejima
Journal:  Neurochem Res       Date:  2018-02-03       Impact factor: 3.996

9.  Stage of the estrous cycle does not influence myocardial ischemia-reperfusion injury in rats (Rattus norvegicus).

Authors:  Chad R Frasier; David A Brown; Ruben C Sloan; Brian Hayes; Luke M Stewart; Hetal D Patel; Robert M Lust; Matthew D Rosenbaum
Journal:  Comp Med       Date:  2013-10       Impact factor: 0.982

Review 10.  Estrogen and the female heart.

Authors:  A A Knowlton; D H Korzick
Journal:  Mol Cell Endocrinol       Date:  2014-01-22       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.